Mathieu Lupien, Senior Scientist at University Health Network, shared on LinkedIn:
“How do you find what drives a cancer subtype that is defined by what it doesn’t have?
That was the challenge Shalini Bahl, Nergiz Dogan-Artun and an incredible team took on with triple-negative breast cancer (TNBC), a disease defined by the absence of the markers that characterize other major breast cancer subtypes. What followed was the discovery of diverse regulatory programs that give each TNBC tumour its identity.
Our new study, published in Nature Portfolio (Nature Communications), shows how combining chromatin accessibility with transcriptional regulatory networks can expose the transcription factor dependencies for individual tumours and how to use those to repurpose existing drugs to help match different TNBCs to tailored treatment options.
The abstract tells the story better than I can.”
Title: A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer
Authors: Shalini Bahl, Nergiz Dogan-Artun, Julia Nguyen, Hassan Mahmoud, Wail Ba-alawi, Seyed Ali Madani Tonekaboni, Komaldeep Kaur Kang, Meghan McGuire, Chantal Tobin, Jennifer Silvester, Paul Savage, Lucie Cressot, Ankita Nand, Guanqiao Feng, Paul Guilhamon, Arvind Singh Mer, Christopher Arlidge, Mitchell J. Elliott, Morag Park, David W. Cescon, Benjamin Haibe-Kains, Mathieu Lupien.
Read the full article.
To which Mitchell Elliott, Instructor at Yale Cancer Center, added:
“Great work, Shalini Bahl!
We are thrilled to welcome you to the team at Yale Cancer Center. I look forward to seeing the incredible impact you will make here with our team.”
Radiotherapy in Breast Cancer LMD: Critical Survival Uncertainty
